For millions of Americans, the diagnosis of Type 2 diabetes or the realization that obesity is threatening their longevity isn’t just a medical hurdle—it’s a financial one. We’ve seen the emails. We’ve heard the phone calls. Patients like “Linda,” a retired teacher from Ohio, who was forced to choose between her prescribed medication and her heating bill during the winter months. This isn’t just a healthcare failure; it’s a call to action. The good news? The landscape is about to change forever with the early 2026 launch of Generic Ozempic (Semaglutide).